Lilly(Eli) & Co(LLY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 14 at 8:05 AM ET (Korea 9/14 21:05)
Full metrics table
| Index | S&P 500 | P/E | 37.91 | EPS (ttm) | 29.43 | Insider Own | 9.88% | Shs Outstand | 941.5M | Perf Week | -3.79% |
| Market Cap | 1050.27B | Forward P/E | 23.93 | EPS next Y | 28.12% | Insider Trans | -0.03% | Shs Float | 848.4M | Perf Month | -8.57% |
| Enterprise Value | 1096.23B | PEG | 0.79 | EPS next Q | 9.85 | Inst Own | 76.27% | Short Float | 0.93% | Perf Quarter | -3.9% |
| Income | 26.71B | P/S | 13.18 | EPS this Y | 50.32% | Inst Trans | -0.01% | Short Ratio | 2.86 | Perf Half Y | 14.17% |
| Sales | 79.67B | P/B | 31.01 | EPS next 5Y | 30.22% | ROA | 21.96% | Short Interest | 7.89M | Perf YTD | 3.82% |
| Book/sh | 35.98 | P/C | 117.35 | EPS past 3/5Y | 49.25% 27.59% | ROE | 102.43% | 52W High | -13.69% ($1292.65) | Perf Year | 47.52% |
| Cash/sh | 9.51 | P/FCF | 57.74 | Sales past 3/5Y | 31.69% 21.58% | ROIC | 32.68% | 52W Low | 56.69% ($712.05) | Perf 3Y | 87.34% |
| Dividend Est. | $6.88 (0.62%) | EV/EBITDA | 26.28 | EPS Y/Y TTM | 95.08% | Gross Margin | 83.4% | Volatility(W/M) | 1.92% 2.61% | Perf 5Y | 365.85% |
| Dividend TTM | 6.69 | EV/Sales | 13.76 | Sales Y/Y TTM | 49.58% | Oper. Margin | 49.72% | ATR (14) | 31.8 | Perf 10Y | 1326% |
| Dividend Ex-Date | 2026/8/14 | Quick Ratio | 1 | EPS Q/Q | 26.2% | Profit Margin | 33.53% | RSI (14) | 35.43 | Recom | 1.56 |
| Dividend Gr. 3/5Y | 15.24% 15.18% | Current Ratio | 1.35 | Sales Q/Q | 47.67% | SMA20 | -5.7% ($1183.14) | Beta | 0.46 | Target Price | $1352.49 |
| Payout | 26.14% | Debt/Eq | 1.62 | Earnings | 2026/8/5 | SMA50 | -5.82% ($1184.65) | Rel Volume | 0.66 | Prev Close | $1123 |
| Employees | 50000 | LT Debt/Eq | 1.41 | EPS/Sales Surpr. | 30.92% 10.33% | SMA200 | 4.78% ($1064.8) | Avg Volume(3M) | 2.76M | Price | $1115.7 |
| IPO | 1970/7/9 | Option/Short | Yes/Yes | Trades | 63131 | Volume | 1,830,671 | Change | -0.65% |
Company
LLY is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 A global large-cap pharmaceutical company with strong positions in diabetes and obesity treatments, as well as oncology, immunology, and neuroscience. Founded in 1876 by Eli Lilly in Indianapolis, Indiana, the company has been a historic pioneer in the commercialization of insulin, and more recently its revenue growth engine has expanded significantly with its obesity and diabetes therapy franchise.
Over the past 1 year, roughly in the middle
14% below its 1-year high.
LLY makes money exceptionally well
49.72% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +50.3% this year.
Tap to view numbers
The price looks about right
Trading at 37.9 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 2 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +87.3% if bought 5 years ago.
Tap to view numbers
The dividend is on the small side
Pays 0.62% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 76.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IHE 0.22%
PPH 0.20%
MEDI 0.20%
MEDX 0.18%
TMED 0.17%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
LLYX 45M
ELIL 16MIt is the largest in the industry
Based on market cap of $1.1T.
LLY $1.1T PER 37.9
JNJ $640B PER 30.8
ABBV $454B PER 72.7
MRK $355B PER 115.0
실적분석 · 8/5 Eli Lilly ($LLY) Q2 2026 Earnings Analysis — Revenue and Adjusted EPS Significantly Beat Estimates; Full-Year Revenue Guidance Raised 투자 가이드 · 4/11 The Complete 2026 Guide to U.S. Dividend Aristocrats 투자 가이드 · 4/1 US Stock Taxes Complete Guide 2026 — Calculation Methods and Tax-Saving Strategies for Beginners See all posts on this stock FAQ
What kind of company is LLY?
LLY belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of LLY?
The market cap of LLY is approximately $1.05T, ranking 14 within its sector.
Does LLY pay dividends?
LLY has a dividend yield of approximately 0.62%, with an annual dividend of $6.88.
What is the P/E ratio of LLY?
LLY has a P/E ratio of approximately 37.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for LLY?
LLY has recorded a 52-week high of $1292.65 and a low of $712.05.
